GSK picks up troubled Spero drug for nearly $300M, takes stake in company

Less than five months after discouraging conversations with the U.S. Food and Drug Administration led Spero Therapeutics Inc. to pause work on a drug and lay off 110 people, the company is licensing that same drug to GSK plc for up to $291 million.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news